About Praxis Precision Medicines, Inc. Common Stock
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Market Cap
$0.77B
Employees
82
Listed Since
October 16, 2020
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.praxismedicines.comPhone
617-300-8460
Headquarters
99 HIGH STREET, 30TH FLOOR
BOSTON, MA 02110
CIK
0001689548
No content available for this security